poisar

Stock

ABBVIE INC. ABBV

$260.19-0.57%

Overview

ABBV market data

Price History

ABBV price chart · 1M
O
263.55
H
263.79
L
257.37
C
260.19
Vol
117,317.00
Source
US equities market feed
Observed
Sep 3, 2026, 12:00 AM
Cadence
Five-minute page cache; daily and stored hourly bars
Status
fresh

Key Stats & Performance

Open
$263.55
Previous Close
$261.68
Day High
$263.79
Day Low
$257.37
52 Week High
$267.45
52 Week Low
$198.77
7 Day Return
+0.79%
30 Day Return
+6.77%
90 Day Return
+15.39%
1 Year Return
+29.31%
Daily Notional Volume
$30.5M
Latest daily bar volume multiplied by its closing price.

Valuation & Profitability

Provider-backed
P/E (TTM)
73.29
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
$2.38
Diluted earnings per share over the trailing twelve months.
Beta
0.20
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
4.5%
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
9.8%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$190.75 – $267.47
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $462.5B · P/B 94.44 · P/S 7.18.

Company News

10 captured
AbbVie Touts Positive Data For Multiple Myeloma DrugBenzinga · Sep 3, 2026, 6:10 PM
AbbVie Affirms FY2026 Adj EPS Guidance of $13.87-$14.07 vs $14.08 EstBenzinga · Sep 3, 2026, 1:17 PM
AbbVie Affirms Q3 Adj EPS Guidance of $3.84-$3.88 vs $3.84 EstBenzinga · Sep 3, 2026, 1:17 PM
Abbvie Announces Topline Results From The Phase 3 Cervino Trial Showing Etentamig Significantly Improved Response Rate And Progression-Free Survival In Patients With Relapsed/Refractory Multiple Myeloma; Etentamig Achieves 74% Orr And 60% Risk Reduction In Phase 3 Cervino Trial; Etentamig Demonstrates Low Rates Of Cytokine Release Syndrome And Fatal Infections; Phase 3 Cervino Study Met Dual Primary Endpoints; Full Results To Be Presented Sept 23-26Benzinga · Sep 3, 2026, 1:16 PM
8-K filing — AbbVie Inc. (ABBV)SEC EDGAR · Sep 3, 2026, 12:47 PM
AbbVie Anticipates Apogee Acquisition To Negatively Impact Adj Diluted EPS By $0.14 This Year, $0.46 In 2027, Accretion Beginning In 2032Benzinga · Sep 3, 2026, 12:46 PM
Healthcare ETF Comparison: Fidelity's FHLC vs. Invesco's Biotech-Focused IBBQThe Motley Fool · Sep 2, 2026, 5:15 PM
AZN Stock Down 20% in 6 Months: How to Play After Pipeline SetbacksZacks Investment Research · Sep 2, 2026, 4:30 PM
Can LLY's Merida Deal Boost Its M&A Push to Diversify Beyond GLP-1s?Zacks Investment Research · Sep 2, 2026, 4:30 PM
Vanguard Health Care ETF vs Simplify Health Care ETFThe Motley Fool · Sep 1, 2026, 8:15 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock